Atyr Pharma Inc. (NASDAQ:LIFE)’s share price dropped 1.4% during trading on Tuesday . The company traded as low as $3.39 and last traded at $3.61, with a volume of 116,867 shares. The stock had previously closed at $3.66.

LIFE has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Atyr Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. BMO Capital Markets reissued a “hold” rating on shares of Atyr Pharma in a research note on Thursday, May 12th. JPMorgan Chase & Co. reduced their price objective on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th. Finally, Citigroup Inc. boosted their price objective on Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.00.

The stock’s market capitalization is $75.66 million. The firm has a 50 day moving average price of $3.01 and a 200-day moving average price of $3.71.

Atyr Pharma (NASDAQ:LIFE) last announced its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.06. Analysts forecast that Atyr Pharma Inc. will post ($2.63) EPS for the current year.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC boosted its position in Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.